Major depression – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:27:46 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Major depression – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Psilocybin and pimavanserin for adults with major depressive disorder https://clinicaltrials.eu/trial/study-of-the-effects-of-psilocybin-and-pimavanserin-in-patients-with-major-depressive-disorder/ Thu, 07 May 2026 05:47:16 +0000 https://clinicaltrials.eu/trial/study-of-the-effects-of-psilocybin-and-pimavanserin-in-patients-with-major-depressive-disorder/ This clinical trial is studying Major depressive disorder, a common form of depression that can cause low mood, loss of interest, and other ongoing emotional symptoms. The trial uses psilocybine, taken by mouth as a capsule, and pimavanserin, taken by mouth as a tablet. Some participants receive psilocybine with pimavanserin, while others receive psilocybine with placebo. The purpose of the study is to understand how psilocybine may affect brain activity in relation to its psychedelic effects, and how this may relate to depression.

The study lasts for several scans over a short period, with brain MRI tests done before and after treatment. MRI is a scan that uses magnetic fields to take pictures of the brain. During the study, changes in brain connections are compared across the different treatment groups. No other study procedures are described here.

]]> Daridorexant for Insomnia in Patients with Major Depressive Disorder and Moderate to Severe Insomnia https://clinicaltrials.eu/trial/a-study-to-evaluate-the-efficacy-and-safety-of-daridorexant-in-patients-with-major-depressive-disorder-and-moderate-to-severe-insomnia/ Thu, 07 May 2026 05:47:16 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-efficacy-and-safety-of-daridorexant-in-patients-with-major-depressive-disorder-and-moderate-to-severe-insomnia/ This clinical trial is studying major depressive disorder and insomnia, which means trouble falling asleep, staying asleep, or getting restful sleep. The treatment being tested is daridorexant, a medicine taken by mouth. It will be compared with placebo during the study.

The purpose of the study is to see whether daridorexant can help improve sleep in people with depression and insomnia, and to check its safety. The study is organized as a double-blind and randomized trial, which means the treatment is assigned by chance and neither the participants nor the study team know which treatment is given during the study. Treatment lasts about 3 months, and sleep and mood are checked during this time to see how the medicine works and whether any side effects occur.

]]> Assessment of NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder https://clinicaltrials.eu/trial/assessment-of-nbi-1065845-as-an-additional-treatment-for-adults-with-major-depressive-disorder/ Mon, 04 May 2026 08:03:55 +0000 https://clinicaltrials.eu/trial/assessment-of-nbi-1065845-as-an-additional-treatment-for-adults-with-major-depressive-disorder/ This study focuses on Major Depressive Disorder (MDD), a mental health condition characterized by persistent feelings of sadness and loss of interest in activities. The research evaluates the medication NBI-1065845 when added to existing antidepressant treatment for adults whose depression has not adequately responded to their current medication.

The purpose of this study is to determine if NBI-1065845 is effective and safe compared to placebo when used as an additional treatment for people with moderate to severe depression. Participants in this study will continue taking their regular antidepressant medication while also receiving either the study drug or placebo.

The study will monitor changes in depression symptoms over an 8-week period. Participants will need to attend regular appointments for evaluations of their depression symptoms using standardized rating scales that measure the severity of depression and how it affects daily functioning.

]]> Evaluating NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder Who Are Not Responding Adequately to Current Therapy https://clinicaltrials.eu/trial/evaluating-nbi-1065845-as-an-additional-treatment-for-adults-with-major-depressive-disorder-who-are-not-responding-adequately-to-current-therapy/ Mon, 04 May 2026 08:03:55 +0000 https://clinicaltrials.eu/trial/evaluating-nbi-1065845-as-an-additional-treatment-for-adults-with-major-depressive-disorder-who-are-not-responding-adequately-to-current-therapy/ This clinical trial is investigating a medication called NBI-1065845 as an additional treatment for adults with Major Depressive Disorder (MDD). Major Depressive Disorder is a mental health condition characterized by persistent feelings of sadness, loss of interest in activities, and other symptoms that significantly affect daily functioning. The purpose of this study is to evaluate how effective and safe NBI-1065845 is when added to existing antidepressant treatments in people whose depression has not adequately responded to their current medication.

The study is designed as a randomized, double-blind trial where participants will receive either NBI-1065845 or a placebo alongside their current antidepressant medication. The treatment period will last for approximately 56 days (8 weeks), during which the medication’s effects on depression symptoms will be monitored.

Participants in this study must have recurrent MDD (occurring multiple times) that is moderate or severe, or persistent depressive disorder (a long-term form of depression). They must already be taking oral antidepressant treatments but experiencing an inadequate response to these medications despite proper dosing and duration.

]]> A study to compare the safety of ketamine hydrochloride and esketamine in healthy men for the treatment of depression https://clinicaltrials.eu/trial/a-study-to-compare-the-safety-of-ketamine-hydrochloride-and-esketamine-in-healthy-men-for-the-treatment-of-depression/ Thu, 30 Apr 2026 13:08:50 +0000 https://clinicaltrials.eu/trial/a-study-to-compare-the-safety-of-ketamine-hydrochloride-and-esketamine-in-healthy-men-for-the-treatment-of-depression/ This study aims to compare how two different medications work in the body for the treatment of Depression. One medication is esketamine, which is given as a nasal spray. The other medication being studied is known as KET01, which is a ketamine hydrochloride prolonged release tablet, meaning the medicine is released slowly into the body over time after being swallowed.

Participants will take part in a process where they receive different treatments at different times. During the study, some individuals will receive the active medications, while others will receive a placebo. The research focuses on how well these substances are tolerated and how they move through the body, specifically looking at dissociative symptoms, which are feelings of being disconnected from one’s body or surroundings.

]]> A study of azetukalner compared to placebo for adults with moderate-to-severe major depressive disorder https://clinicaltrials.eu/trial/a-study-of-azetukalner-compared-to-placebo-for-adults-with-moderate-to-severe-major-depressive-disorder/ Thu, 30 Apr 2026 13:08:37 +0000 https://clinicaltrials.eu/trial/a-study-of-azetukalner-compared-to-placebo-for-adults-with-moderate-to-severe-major-depressive-disorder/ This study is looking at Major Depressive Disorder, which is a mental health condition that causes persistent feelings of sadness and loss of interest in activities. The study will test a medication called azetukalner, which is also known as XPF-010. Some participants will receive azetukalner while others will receive placebo. The purpose of the study is to see if azetukalner works effectively in treating moderate-to-severe Major Depressive Disorder.

Participants will take either azetukalner capsules or placebo capsules by mouth once daily for a period of time. The dose of azetukalner that will be used is 20 milligrams per day. The study will measure changes in depression symptoms over several weeks, with particular attention to how participants feel after six weeks of treatment. The study will also look at changes in the ability to feel pleasure and overall improvement in the severity of depression symptoms.

This is a randomized, double-blind, placebo-controlled study, which means that participants will be assigned by chance to receive either the active medication or placebo, and neither the participants nor the doctors will know which treatment is being given until the study is completed. The treatment period will last up to 18 months. Participants may also continue taking their regular antidepressant medication during the study.

]]> A study testing intranasal esketamine compared to midazolam for rapidly reducing symptoms of major depressive disorder in adolescents with suicidal thoughts or behavior https://clinicaltrials.eu/trial/a-study-testing-intranasal-esketamine-compared-to-midazolam-for-rapidly-reducing-symptoms-of-major-depressive-disorder-in-adolescents-with-suicidal-thoughts-or-behavior/ Thu, 30 Apr 2026 13:08:26 +0000 https://clinicaltrials.eu/trial/a-study-testing-intranasal-esketamine-compared-to-midazolam-for-rapidly-reducing-symptoms-of-major-depressive-disorder-in-adolescents-with-suicidal-thoughts-or-behavior/ This study is looking at Major Depressive Disorder in teenagers who are having thoughts of suicide or suicidal behavior. Major Depressive Disorder is a condition where a person feels very sad and hopeless for long periods of time, which can affect their daily life. The study will test a medicine called esketamine, which is given as a nasal spray into the nose. Some participants will receive esketamine while others will receive either an oral placebo or an intranasal placebo. Additionally, some participants will receive midazolam, which is given by mouth as a liquid solution. All participants will also receive standard care treatment, which includes being in the hospital and taking one of several antidepressant medicines such as fluoxetine, escitalopram, or sertraline.

The purpose of this study is to see if esketamine can quickly reduce the symptoms of depression in teenagers who are having serious thoughts about suicide. The study will compare how well esketamine works compared to the other treatments when added to the standard care that these teenagers receive.

During the study, participants will be admitted to the hospital for about five days. They will receive their assigned treatment on the first day, and doctors will measure changes in their depression symptoms over the following 24 hours and beyond. Throughout the study, participants will continue to receive the standard care treatment including their prescribed antidepressant medicine and support from healthcare professionals.

]]> A study on ketamine maintenance treatment for patients with treatment-resistant major depression disorder https://clinicaltrials.eu/trial/a-study-on-ketamine-maintenance-treatment-for-patients-with-treatment-resistant-major-depression-disorder/ Thu, 30 Apr 2026 13:08:22 +0000 https://clinicaltrials.eu/trial/a-study-on-ketamine-maintenance-treatment-for-patients-with-treatment-resistant-major-depression-disorder/ This study is looking at Major Depression Disorder, which is a condition where people experience persistent feelings of sadness, loss of interest in activities, and other symptoms that affect daily life. The study focuses specifically on treatment-resistant depression, which means depression that has not improved enough with at least two different types of treatments such as medications, talking therapy, or brain stimulation treatments. The medication being tested in this study is ketamine hydrochloride, which will be given through an infusion, meaning it will be delivered directly into a vein over a period of time. The study will also include people who have bipolar-2 disorder, which is a condition involving mood changes between depression and less severe elevated moods.

The purpose of this study is to examine how well long-term maintenance treatment with ketamine works for keeping depression symptoms from coming back after an initial treatment period. The study is designed to compare different treatment approaches over time to see which one is most effective at preventing depression from returning. Participants will be divided into three different treatment groups to compare the results. The study will look at how long it takes for depression symptoms to come back after the initial treatment phase and after the last ketamine infusion, using a depression rating scale to measure symptom severity.

During the study, participants will receive ketamine infusions according to their assigned treatment group, with the treatment lasting up to 10 days in total. The maximum daily dose will be 150 milligrams, and the maximum total dose across all infusions will be 2700 milligrams. Throughout the study, doctors will monitor participants for any unwanted effects or reactions to the treatment through interviews, observations, questionnaires, and review of medical records. Women who could become pregnant must have a negative pregnancy test before starting the study and before each maintenance ketamine infusion, and must use highly effective birth control methods throughout their participation in the study.

]]> A Study of Brexanolone Caprilcerbate for Adults with Major Depressive Disorder With or Without Anxious Distress https://clinicaltrials.eu/trial/a-study-of-brexanolone-caprilcerbate-for-adults-with-major-depressive-disorder-with-or-without-anxious-distress/ Thu, 30 Apr 2026 13:08:19 +0000 https://clinicaltrials.eu/trial/a-study-of-brexanolone-caprilcerbate-for-adults-with-major-depressive-disorder-with-or-without-anxious-distress/ This study is looking at adults who have Major Depressive Disorder, which is a mental health condition that causes persistent feelings of sadness and loss of interest in daily activities. Some people with this condition may also experience anxious distress, which means they feel worried, tense, or restless along with their depression. The treatment being tested is called SPT-300, which is given as a capsule taken by mouth. The active ingredient in this medication is brexanolone caprilcerbate. The purpose of this study is to check how safe this medication is and whether people can tolerate it well when they take it over a period of time.

This is an extension study, which means it is designed for people who have already completed another study with the same medication. Participants will take SPT-300 for six weeks, and everyone in the study will receive the active medication rather than a placebo. The study is described as open-label, which means both the participants and the doctors will know what treatment is being given. During the study, participants will have regular visits where doctors will check for any unwanted effects, measure vital signs like blood pressure and heart rate, and perform blood tests and physical examinations. The doctors will also use questionnaires to assess mood, anxiety levels, and how the condition affects daily life.

Throughout the six weeks, the medical team will carefully monitor participants for any side effects or health changes. Special attention will be given to thoughts of self-harm using a specific rating scale designed for this purpose. The study will also look at whether symptoms of depression and anxiety improve over time. Participants will need to avoid alcohol and recreational drugs during the study and must use effective birth control methods if they are able to have children. The maximum daily dose of the medication is 375 milligrams, and treatment will continue for the full six-week period.

]]> Study of lavender oil (Silexan) in patients with mild to moderate major depressive disorder comparing its effectiveness to placebo https://clinicaltrials.eu/trial/study-of-lavender-oil-silexan-in-patients-with-mild-to-moderate-major-depressive-disorder-comparing-its-effectiveness-to-placebo/ Thu, 30 Apr 2026 13:08:08 +0000 https://clinicaltrials.eu/trial/study-of-lavender-oil-silexan-in-patients-with-mild-to-moderate-major-depressive-disorder-comparing-its-effectiveness-to-placebo/ This study examines the use of Silexan, a lavender oil medication, in people with Major Depressive Disorder of mild to moderate severity. The study will evaluate whether taking a daily 80 mg soft capsule of Silexan works better than a placebo in reducing depression symptoms.

The purpose of this research is to determine if Silexan is effective and safe for treating mild to moderate depression. During the study, participants will take either Silexan or a placebo capsule once daily for 8 weeks. The depression symptoms will be monitored throughout the study period using various assessment tools that measure the severity of depression and how it affects daily life.

The study will track any changes in depression symptoms and monitor the overall safety of the treatment. Researchers will observe how participants respond to the medication, including whether their depression symptoms improve or if they achieve remission (very low levels of depression symptoms). They will also keep track of any side effects that may occur during the treatment period.

]]> Study of milsaperidone as an additional treatment for adults with Major Depressive Disorder who are already taking antidepressants https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-milsaperidone-as-an-additional-treatment-for-patients-with-major-depressive-disorder/ Thu, 30 Apr 2026 13:07:56 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-milsaperidone-as-an-additional-treatment-for-patients-with-major-depressive-disorder/ This study focuses on Major Depressive Disorder (MDD), a serious mental health condition characterized by persistent feelings of sadness and loss of interest in daily activities. The research evaluates a new medication called milsaperidone (also known as VHX-896) when used together with existing antidepressant therapy in people whose depression has not adequately improved with current treatment.

The study tests whether taking milsaperidone tablets along with a person’s current antidepressant medication helps improve depression symptoms better than taking a placebo with the antidepressant. The medication or placebo will be given as oral tablets, with participants receiving treatment for 6 weeks.

This is a double-blind study where participants will continue their current antidepressant medication while also receiving either milsaperidone or placebo tablets. The main goal is to determine if adding milsaperidone to existing antidepressant treatment helps reduce depression symptoms in people who haven’t responded well enough to their current medication alone.

]]> A study of ketamine hydrochloride as an additional treatment for patients starting standard antidepressants for major depression https://clinicaltrials.eu/trial/a-study-of-ketamine-hydrochloride-as-an-additional-treatment-for-patients-starting-standard-antidepressants-for-major-depression/ Wed, 29 Apr 2026 15:09:18 +0000 https://clinicaltrials.eu/trial/a-study-of-ketamine-hydrochloride-as-an-additional-treatment-for-patients-starting-standard-antidepressants-for-major-depression/ This study focuses on individuals living with Major Depressive Disorder, a mental health condition that causes persistent feelings of sadness and a loss of interest in activities. The purpose of the study is to evaluate the early effectiveness of a new treatment used alongside standard antidepressant medications. The treatment being tested is a medication called KET01, which is a ketamine hydrochloride prolonged release tablet. This specific form of medicine is designed to release the drug into the body slowly over time through oral intake.

During the trial, participants will take the KET01 tablets in addition to their usual antidepressant therapy. The course of the study involves regular check-ins to monitor how the combination of medications affects mood and overall well-being over a period of several weeks.

]]> A study to evaluate the effectiveness and safety of DT-101 in adults with major depressive disorder https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-dt-101-in-adults-with-major-depressive-disorder/ Wed, 29 Apr 2026 15:09:08 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-dt-101-in-adults-with-major-depressive-disorder/ This study focuses on Major Depressive Disorder, a mental health condition characterized by persistent feelings of sadness and a loss of interest in daily activities. The purpose of the study is to evaluate the effects of different dose levels of the experimental medicine DT-101 compared to a placebo in treating symptoms of this condition.

Participants in the study will take a capsule by mouth. During the trial, some individuals will receive the active substance DT-101, while others will receive a placebo. This research will examine how the medicine works in the body and its safety profile over time.

]]> Testing Ulotaront Added to Antidepressants for Adults with Major Depressive Disorder Who Did Not Respond Well to Initial Treatment https://clinicaltrials.eu/trial/testing-ulotaront-added-to-antidepressants-for-adults-with-major-depressive-disorder-who-did-not-respond-well-to-initial-treatment/ Wed, 29 Apr 2026 15:08:24 +0000 https://clinicaltrials.eu/trial/testing-ulotaront-added-to-antidepressants-for-adults-with-major-depressive-disorder-who-did-not-respond-well-to-initial-treatment/ This study involves people who have Major Depressive Disorder, a condition where a person experiences persistent feelings of sadness and loss of interest in activities that affects daily life. The study will test a medication called Ulotaront, also known by its code name SEP-363856, which will be given as an additional treatment alongside standard antidepressant medications. The antidepressants that may be used in this study include venlafaxine, citalopram, sertraline, duloxetine, fluoxetine, and paroxetine. Some people in the study will receive placebo instead of the study medication. The purpose of this study is to find out if SEP-363856 works better than placebo when added to standard antidepressant treatment in helping people whose depression has not improved enough with their current antidepressant medication.

The study is divided into two phases and lasts for about 14 weeks in total. During the first phase, which lasts 8 weeks, all people in the study will receive one of the standard antidepressant medications mentioned above. This phase helps to confirm that the depression has not improved enough with the antidepressant alone. During the second phase, which lasts 6 weeks, people will continue taking their antidepressant medication and will also receive either SEP-363856 or placebo. All medications are taken by mouth. The study will measure changes in depression symptoms using rating scales that assess mood, daily functioning, and overall well-being.

Throughout the study, regular check-ups will be conducted to monitor safety. These check-ups include physical examinations, measurements of body weight, blood pressure, heart rate, and body temperature. Blood and urine samples will be collected to check general health and how the body is processing the medications. Heart activity will be monitored using a test that records the electrical signals of the heart. The study will also assess other aspects such as movement-related side effects, sleep quality, sexual functioning, and thoughts about self-harm. People in the study will be asked about any unwanted effects they may experience.

]]> A Study of SPT-300 Compared to Placebo for Adults with Major Depressive Disorder with or without Anxious Distress https://clinicaltrials.eu/trial/a-study-of-spt-300-compared-to-placebo-for-adults-with-major-depressive-disorder-with-or-without-anxious-distress/ Wed, 29 Apr 2026 15:08:22 +0000 https://clinicaltrials.eu/trial/a-study-of-spt-300-compared-to-placebo-for-adults-with-major-depressive-disorder-with-or-without-anxious-distress/ This study is looking at Major Depressive Disorder, which is a condition where people experience persistent feelings of sadness and loss of interest in activities that can affect daily life. Some people with this condition may also experience anxious distress, which means having feelings of worry or tension along with their depression. The study will test a medication called SPT-300, which contains brexanolone caprilcerbate, and compare it to placebo. The medication comes in capsule form and is taken by mouth.

The purpose of this study is to see how well SPT-300 works as a single treatment for reducing symptoms of depression in adults who have Major Depressive Disorder, whether or not they also have anxious distress. The study will also look at how safe the medication is and how well people tolerate it. Researchers want to understand if this treatment can help improve the symptoms that people with depression experience.

During the study, participants will be randomly assigned to receive either SPT-300 or placebo. The study is double-blind, which means neither the participants nor the doctors will know who is receiving which treatment. Participants will take the medication for a period of time, with the maximum daily amount being 375 milligrams. The treatment period can last up to six months. Throughout the study, participants will have regular visits where doctors will assess their depression symptoms and overall condition to see if there are any changes. The study will measure depression symptoms using standard rating scales to determine if the treatment is working.

]]> Study of D-cycloserine with theta-burst brain stimulation for adults with major depressive disorder https://clinicaltrials.eu/trial/study-of-d-cycloserine-with-theta-burst-brain-stimulation-for-adults-with-major-depressive-disorder/ Wed, 29 Apr 2026 15:07:30 +0000 https://clinicaltrials.eu/trial/study-of-d-cycloserine-with-theta-burst-brain-stimulation-for-adults-with-major-depressive-disorder/ This study focuses on treating patients with Major Depressive Disorder, a serious mental health condition characterized by persistent feelings of sadness and loss of interest in daily activities. The research combines two treatments: a technique called accelerated intermittent theta-burst stimulation (a form of brain stimulation) and D-cycloserine, a medication given as oral capsules.

The study aims to determine if adding daily 100 mg D-cycloserine capsules improves the effectiveness of brain stimulation treatment compared to a placebo in reducing depression symptoms. The treatment period lasts for nine weekdays, during which participants receive both brain stimulation and either the medication or placebo capsules. The placebo capsules look identical to the real medication but contain an inactive substance.

Participants will be monitored for changes in their depression symptoms through various assessments over a period of 180 days. The study includes regular check-ups to evaluate mood, anxiety levels, daily functioning, and overall well-being. Throughout the study, participants will take either D-cycloserine or placebo capsules, but neither the participants nor the healthcare providers will know which one they are receiving until the study is complete.

]]> Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder https://clinicaltrials.eu/trial/safety-and-tolerability-study-of-nbi-1065845-as-additional-treatment-for-adults-with-major-depressive-disorder/ Wed, 29 Apr 2026 15:06:58 +0000 https://clinicaltrials.eu/trial/safety-and-tolerability-study-of-nbi-1065845-as-additional-treatment-for-adults-with-major-depressive-disorder/ This study focuses on people with Major Depressive Disorder (MDD), a serious mental health condition characterized by persistent feelings of sadness and loss of interest in daily activities. The research evaluates a new medication called NBI-1065845 when used together with existing antidepressant treatments in adults who have not responded well enough to current antidepressant medications alone.

The purpose of this research is to assess how safe and well-tolerated NBI-1065845 is when taken as an additional treatment alongside regular antidepressant medication. The study medication comes in the form of oral tablets that participants take along with their current antidepressant treatment.

This is a long-term study that lasts for approximately 52 weeks (one year). During this time, all participants receive the study medication NBI-1065845 while continuing their current antidepressant treatment at the same dose they were taking before joining the study. The study team monitors participants’ health and any side effects that may occur throughout the treatment period.

]]> Study of deupsilocin besilate (CYB003) in adults with major depressive disorder comparing two doses against placebo https://clinicaltrials.eu/trial/study-of-deupsilocin-besilate-cyb003-in-adults-with-major-depressive-disorder-comparing-two-doses-against-placebo/ Wed, 29 Apr 2026 15:06:57 +0000 https://clinicaltrials.eu/trial/study-of-deupsilocin-besilate-cyb003-in-adults-with-major-depressive-disorder-comparing-two-doses-against-placebo/ This clinical trial investigates a new treatment for Major Depressive Disorder, a serious mental health condition characterized by persistent feelings of sadness and loss of interest in daily activities. The study tests a medication called CYB003 (containing deupsilocin besilate) given as oral capsules, comparing it with placebo to evaluate its effectiveness in treating depression symptoms.

The purpose of this research is to assess how well two different doses of CYB003 work compared to placebo in treating adults with depression. The study medication will be given twice over a period of several weeks, with participants receiving either CYB003 capsules (8 mg or 16 mg) or placebo capsules. Throughout the study, participants will continue taking their current antidepressant medication.

During the trial, participants will attend multiple clinic visits where their depression symptoms will be evaluated using various assessment tools. The study will track changes in depression symptoms over 84 days to determine if the treatment is effective. The medication’s safety will also be monitored throughout the study period.

]]> Study of NBI-1065845 as add-on treatment to prevent depression relapse in adults with Major Depressive Disorder who responded to initial treatment https://clinicaltrials.eu/trial/study-of-nbi-1065845-as-add-on-treatment-to-prevent-depression-relapse-in-adults-with-major-depressive-disorder-who-responded-to-initial-treatment/ Wed, 29 Apr 2026 15:06:42 +0000 https://clinicaltrials.eu/trial/study-of-nbi-1065845-as-add-on-treatment-to-prevent-depression-relapse-in-adults-with-major-depressive-disorder-who-responded-to-initial-treatment/ This study focuses on people with Major Depressive Disorder (MDD) who have not responded well enough to their current antidepressant medications. The research evaluates a new medication called NBI-1065845, which is being tested as an additional treatment alongside existing antidepressant therapy. The study aims to determine if this new medication can help prevent depression symptoms from returning in people who have shown improvement with the treatment.

The study involves two phases. In the first phase, all participants receive NBI-1065845 along with their current antidepressant medication. Those who show improvement then continue to the second phase, where they are randomly assigned to either continue taking NBI-1065845 or receive a placebo, while maintaining their regular antidepressant medication. The treatment period lasts for 33 months.

The medication being studied, NBI-1065845, comes in tablet form and is taken by mouth. This research specifically looks at people who have experienced recurring episodes of moderate to severe depression or have persistent depressive symptoms, despite being on antidepressant treatment. The study will track how long it takes for depression symptoms to return, if they do, after participants start the second phase of the study.

]]> Long-term safety and effectiveness study of CYB003 (deupsilocin besilate) with optional additional doses for people with Major Depressive Disorder https://clinicaltrials.eu/trial/long-term-safety-and-effectiveness-study-of-cyb003-deupsilocin-besilate-with-optional-additional-doses-for-people-with-major-depressive-disorder/ Wed, 29 Apr 2026 15:06:25 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-effectiveness-study-of-cyb003-deupsilocin-besilate-with-optional-additional-doses-for-people-with-major-depressive-disorder/ This clinical trial focuses on studying a medication called CYB003 for people with Major Depressive Disorder. The medication contains deupsilocin besilate and comes in capsule form that is taken by mouth. The study aims to examine how long the medication’s benefits last after initial treatment and whether additional doses might help maintain its effectiveness.

The study is designed as a long-term extension trial, which means it continues to follow participants who have completed previous studies of the same medication. During the trial, participants may receive up to three additional doses of CYB003 while continuing their regular antidepressant medication. The maximum daily dose of the study medication is 16 milligrams, and the treatment period can last up to 43 days.

Throughout the study, researchers will monitor how well participants maintain their improvement in depression symptoms and how quickly symptoms might return, if at all. They will also track whether participants who didn’t respond well to the initial treatment might benefit from additional doses. The study will evaluate both the safety of the medication and how well it works over a longer period.

]]> Study on the Effectiveness and Safety of NBI-1065845 for Adults with Major Depressive Disorder https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-nbi-1065845-for-adults-with-major-depressive-disorder/ Wed, 29 Apr 2026 15:05:59 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-nbi-1065845-for-adults-with-major-depressive-disorder/ This clinical trial is focused on studying the effects of a new treatment for Major Depressive Disorder (MDD), a condition characterized by persistent feelings of sadness and loss of interest in daily activities. The treatment being tested is a medication called NBI-1065845, which is taken in tablet form. The study will compare the effects of this medication to a placebo to determine its effectiveness and safety when used alongside existing antidepressant treatments.

The purpose of the study is to evaluate how well NBI-1065845 can improve symptoms of depression in individuals with MDD. Participants will be randomly assigned to receive either the medication or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. The study will last for a total of 56 days, during which participants will continue their current antidepressant medications while taking the study medication or placebo.

Throughout the study, participants will be monitored to assess changes in their depression symptoms using a tool called the Montgomery-Asberg Depression Rating Scale (MADRS). The study aims to see if there is a significant improvement in depression symptoms by the end of the 56-day period. Additionally, other measures of daily functioning and overall severity of depression will be evaluated to provide a comprehensive understanding of the treatment’s impact.

]]> Study on the Effects of Escitalopram and Bupropion on Dopamine Levels in Patients with Major Depression https://clinicaltrials.eu/trial/study-on-the-effects-of-escitalopram-and-bupropion-on-dopamine-levels-in-patients-with-major-depression/ Wed, 29 Apr 2026 15:05:25 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-escitalopram-and-bupropion-on-dopamine-levels-in-patients-with-major-depression/ This clinical trial is focused on studying changes in brain chemistry related to rewards in individuals with Major Depression and healthy volunteers. The study will explore how two different medications, escitalopram and bupropion, affect the brain’s reward system in people with depression. Escitalopram is commonly known as Cipralex®, and bupropion is known as Wellbutrin XR®. Both medications are used to treat depression, but they work in different ways.

The purpose of the study is to understand how these medications influence the production of a brain chemical called dopamine, which is important for feeling pleasure and motivation. Participants will be given either escitalopram, bupropion, or a placebo, and their brain activity will be monitored over time. The study will use a special brain scan to measure changes in dopamine levels in a part of the brain called the nucleus accumbens, which is involved in the reward system.

Participants will be involved in the study for a period of time, during which they will take the medication and undergo regular assessments to track changes in their symptoms and brain activity. The study aims to provide insights into how these medications can help improve symptoms of depression by affecting the brain’s reward system. This research could lead to better understanding and treatment options for people with Major Depression.

]]> Study on the Effects of D-Cycloserine and Brain Stimulation for Patients with Major Depressive Disorder https://clinicaltrials.eu/trial/study-on-the-effects-of-d-cycloserine-and-brain-stimulation-for-patients-with-major-depressive-disorder/ Wed, 29 Apr 2026 15:05:08 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-d-cycloserine-and-brain-stimulation-for-patients-with-major-depressive-disorder/ This clinical trial is focused on studying the effects of a treatment for Major Depressive Disorder (MDD), a condition characterized by persistent feelings of sadness and loss of interest. The study will explore the use of a medication called D-cycloserine (DCS) in combination with a technique known as transcranial magnetic stimulation (TMS). TMS is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain, which may help improve symptoms of depression.

The purpose of the study is to investigate whether adding D-cycloserine to a single day of accelerated TMS can enhance its antidepressant effects. Participants will receive either the medication or a placebo alongside TMS. The study will monitor changes in depression symptoms over a period of six weeks, with follow-up assessments at six months to evaluate the long-term effects of the treatment.

Throughout the study, participants will be asked to complete various questionnaires and tests to assess their mood, anxiety levels, and cognitive performance. These assessments will help researchers understand the impact of the treatment on different aspects of mental health. The study aims to provide valuable insights into improving treatment options for individuals with Major Depressive Disorder.

]]> Study on Thiopental Sodium Dose During Electroconvulsive Therapy for Patients with Major Depressive Disorder https://clinicaltrials.eu/trial/study-on-thiopental-sodium-dose-during-electroconvulsive-therapy-for-patients-with-major-depressive-disorder/ Wed, 29 Apr 2026 15:04:16 +0000 https://clinicaltrials.eu/trial/study-on-thiopental-sodium-dose-during-electroconvulsive-therapy-for-patients-with-major-depressive-disorder/ This clinical trial is focused on studying the effects of different doses of the anesthetic medication thiopental sodium during electroconvulsive therapy (ECT) for patients with major depressive disorder. Major depressive disorder, often referred to as depression, is a mental health condition characterized by persistent feelings of sadness and loss of interest. The trial aims to determine if using a lower dose of thiopental sodium during ECT can lead to a greater reduction in depressive symptoms compared to a higher dose.

Participants in the study will undergo six sessions of ECT, a treatment that involves sending small electric currents through the brain to trigger a brief seizure, which can help alleviate symptoms of depression. The study will compare the effects of a low dose versus a high dose of thiopental sodium on the reduction of depressive symptoms. Additionally, the study will observe other factors such as the duration of seizures, cognitive side effects, the total number of ECT sessions needed, length of hospital stay, awareness during anesthesia, and the risk of depression returning within a year after treatment.

The purpose of this study is to explore whether adjusting the dose of thiopental sodium can improve the outcomes of ECT for patients with major depressive disorder. The trial will provide valuable insights into optimizing ECT treatment to enhance its effectiveness and minimize potential side effects for individuals suffering from depression.

]]> Study on Seltorexant for Adults and Elderly with Major Depressive Disorder and Insomnia Symptoms https://clinicaltrials.eu/trial/study-on-seltorexant-for-adults-and-elderly-with-major-depressive-disorder-and-insomnia-symptoms/ Wed, 29 Apr 2026 15:03:59 +0000 https://clinicaltrials.eu/trial/study-on-seltorexant-for-adults-and-elderly-with-major-depressive-disorder-and-insomnia-symptoms/ This clinical trial is focused on studying the effects of a medication called seltorexant on adults and elderly patients who have Major Depressive Disorder with symptoms of insomnia. Major Depressive Disorder, often referred to as depression, is a condition characterized by persistent feelings of sadness and loss of interest, which can significantly impact daily life. Insomnia is a common symptom of depression, where individuals have trouble falling or staying asleep.

The purpose of the study is to evaluate how well seltorexant works when used alongside other antidepressants, specifically those known as SSRIs (Selective Serotonin Reuptake Inhibitors) or SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors). The study will compare the effects of taking seltorexant with a placebo, which looks like the medication but does not contain the active ingredient. The study aims to see if seltorexant can improve depressive symptoms and help maintain these improvements over time.

Participants in the study will take part in two main parts. In the first part, the effectiveness of seltorexant in improving symptoms of depression will be assessed. In the second part, the focus will be on whether seltorexant can help prevent the return of depressive symptoms after initial improvement. The study will involve taking the medication in the form of a film-coated tablet by mouth. The trial is designed to ensure the safety and effectiveness of seltorexant as an additional treatment for those who have not fully responded to their current antidepressant therapy.

]]> Study on the Safety and Effectiveness of Dexamfetamine Sulfate for Adults with ADHD and Moderate to Severe Depression https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-dexamfetamine-sulfate-for-adults-with-adhd-and-moderate-to-severe-depression/ Wed, 29 Apr 2026 15:03:50 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-dexamfetamine-sulfate-for-adults-with-adhd-and-moderate-to-severe-depression/ This clinical trial is focused on studying the effects of two formulations of dexamfetamine sulfate in adults who have both Attention Deficit Hyperactivity Disorder (ADHD) and moderate to severe depression. The study aims to understand the safety and effectiveness of these medications. Participants will receive either the medication or a placebo, which looks like the medication but does not contain the active ingredient. The medications being tested are Dexamfetamine sulfate 10 mg, 15 mg, and 20 mg modified-release capsules and Attentin 5 mg and 10 mg tablets.

The purpose of the study is to assess the occurrence of any side effects in those taking the active medications compared to those taking the placebo. The study will take place over several visits, where participants will be monitored for any changes in their condition and any side effects they might experience. The study will last for a maximum of 12 weeks, during which participants will be asked to take the medication or placebo daily.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their symptoms. The goal is to gather information on how well the medications work and how safe they are for people with both ADHD and depression. This information will help in understanding the potential benefits and risks of using dexamfetamine sulfate for treating these conditions together.

]]> Study on the Effects of Venlafaxine and Gut Microbiome in Patients with Major Depressive Disorder https://clinicaltrials.eu/trial/study-on-the-effects-of-venlafaxine-and-gut-microbiome-in-patients-with-major-depressive-disorder/ Wed, 29 Apr 2026 15:03:36 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-venlafaxine-and-gut-microbiome-in-patients-with-major-depressive-disorder/ This clinical trial focuses on studying Major Depressive Disorder, a common mental health condition characterized by persistent feelings of sadness and loss of interest. The study will use a medication called Venlafaxine, which is commonly prescribed to help alleviate symptoms of depression. The purpose of the study is to explore how the community of bacteria in the gut, known as the gut microbiome, is related to the effectiveness of depression treatment and any side effects experienced.

Participants in the study will begin a new treatment with Venlafaxine and will be monitored to see how their gut microbiome changes in response to the medication. The study aims to find out if these changes in the gut bacteria are linked to improvements in depression symptoms and any side effects that may occur. Additionally, the study will look at how the levels of the medication in the blood might influence these changes and the overall effectiveness of the treatment.

The study will take place over a period of time, with participants being observed for changes in their symptoms and gut microbiome. The goal is to better understand the relationship between the gut microbiome and depression treatment, which could lead to more effective ways to manage the condition in the future.

]]> Study on the Effects of Minocycline on Inflammation in Patients with Depression https://clinicaltrials.eu/trial/study-on-the-effects-of-minocycline-on-inflammation-in-patients-with-depression/ Wed, 29 Apr 2026 15:03:32 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-minocycline-on-inflammation-in-patients-with-depression/ This clinical trial is focused on studying the effects of the medication Minocycline on patients with Depression. Depression is a common mental health condition that affects mood and overall well-being. The study aims to see if Minocycline can help reduce inflammation in the body, which is thought to be linked to depression. Minocycline is an antibiotic that is being tested for its potential benefits beyond treating infections.

The purpose of the study is to evaluate whether Minocycline can improve the inflammatory status in patients with depression when added to their current treatment. Participants will receive Minocycline for a period of eight weeks. During this time, researchers will monitor changes in inflammation levels and depressive symptoms. The study will also use imaging techniques like PET and MRI to observe any changes in the brain’s structure and function.

Throughout the study, participants will continue their usual depression treatment while taking Minocycline. The researchers will assess the effects of the medication by comparing inflammation and depression symptoms before and after the treatment period. This study hopes to provide insights into how Minocycline might help manage depression by targeting inflammation.

]]> Study on Stopping Antidepressants: Comparing Tapering Methods for Patients with Major Depressive Disorder Using Venlafaxine or Paroxetine Hydrochloride https://clinicaltrials.eu/trial/study-on-stopping-antidepressants-comparing-tapering-methods-for-patients-with-major-depressive-disorder-using-venlafaxine-or-paroxetine-hydrochloride/ Wed, 29 Apr 2026 15:01:59 +0000 https://clinicaltrials.eu/trial/study-on-stopping-antidepressants-comparing-tapering-methods-for-patients-with-major-depressive-disorder-using-venlafaxine-or-paroxetine-hydrochloride/ This clinical trial is focused on individuals with Major Depressive Disorder (MDD), a condition characterized by persistent feelings of sadness and loss of interest. The study is examining the best ways to stop using certain antidepressants, specifically Venlafaxine and Paroxetine Hydrochloride. These medications are commonly used to treat depression, and the trial aims to find effective methods for discontinuing their use in patients who have been stable and in remission from MDD for a significant period.

The purpose of the study is to compare two different strategies for tapering off these antidepressants. Participants will be randomly assigned to one of the two strategies, and some may receive a placebo. The trial will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving which treatment. This approach helps ensure the results are unbiased and reliable.

The study will last for several months, during which participants will gradually reduce their medication under close supervision. The main focus will be on the rate of failure to successfully discontinue the antidepressant, which includes any significant withdrawal symptoms or the need to switch to another medication. The trial will help determine the most effective and safe way to stop using these medications for those who have achieved remission from MDD.

]]> Study on Esketamine and Aripiprazole with Antidepressants for Treatment-Resistant Depression in Elderly Patients https://clinicaltrials.eu/trial/study-on-esketamine-and-aripiprazole-with-antidepressants-for-treatment-resistant-depression-in-elderly-patients/ Wed, 29 Apr 2026 15:01:54 +0000 https://clinicaltrials.eu/trial/study-on-esketamine-and-aripiprazole-with-antidepressants-for-treatment-resistant-depression-in-elderly-patients/ This clinical trial is focused on studying treatments for refractory major depressive disorder (RMDD) in elderly patients. RMDD is a type of depression that does not improve with standard treatments. The study will compare two treatments: esketamine nasal spray and aripiprazole, both used alongside an antidepressant. Esketamine is administered as a nasal spray, while aripiprazole is available in tablet form or as an oral solution.

The purpose of the study is to evaluate the effectiveness of these treatments over an eight-week period. Participants will continue taking their current antidepressant medication while adding either esketamine or aripiprazole to their treatment plan. The study aims to see if these additional treatments can help reduce symptoms of depression in patients who have not responded well to other antidepressants.

Throughout the study, participants will be monitored to assess their response to the treatment and any changes in their depressive symptoms. The study will also look at the safety of the treatments and their impact on the participants’ quality of life. The trial will last for up to 32 weeks, with regular check-ins to track progress and any potential side effects. The goal is to find a more effective treatment option for elderly patients with RMDD who have not found relief with other medications.

]]> Study on the Effectiveness and Safety of Intranasal BPL-003 for Patients with Treatment-Resistant Depression https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-intranasal-bpl-003-for-patients-with-treatment-resistant-depression/ Wed, 29 Apr 2026 14:59:07 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-intranasal-bpl-003-for-patients-with-treatment-resistant-depression/ This clinical trial is focused on studying a condition known as Treatment-Resistant Depression (TRD). TRD is a type of depression that does not improve after trying at least two different treatments. The study is testing a new treatment called BPL-003, which is a nasal powder containing the active substance mebufotenin benzoate. This treatment is being developed by Beckley Psytech Ltd and is administered through the nose.

The purpose of the study is to evaluate how effective and safe BPL-003 is for people with TRD. Participants will receive the treatment along with psychological support. The study will have two parts: an initial phase to determine how well the treatment works and a follow-up phase to assess its safety. During the study, participants will be monitored for any changes in their depression symptoms and any side effects they might experience.

Participants will be asked to attend several study visits where they will receive the treatment and undergo assessments. These assessments will help researchers understand how the treatment affects depression symptoms and overall health. The study aims to provide valuable information on whether BPL-003 can be a helpful option for people with TRD who have not found relief with other treatments.

]]> Study on the Effects of BH-200 (Nelivaptan) for Patients with Major Depressive Disorder https://clinicaltrials.eu/trial/study-on-the-effects-of-bh-200-nelivaptan-for-patients-with-major-depressive-disorder/ Wed, 29 Apr 2026 14:59:06 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-bh-200-nelivaptan-for-patients-with-major-depressive-disorder/ This clinical trial is focused on studying the effects of a medication called Nelivaptan on individuals with Major Depressive Disorder (MDD). MDD is a mental health condition characterized by persistent feelings of sadness and loss of interest in activities. The study aims to evaluate how effective and tolerable a fixed dose of Nelivaptan, also known by its code name BH-200, is in improving symptoms of depression in patients who have a specific genetic profile related to the V1b receptor.

The trial will last for 14 weeks, with an 8-week period where participants will receive either Nelivaptan or a placebo. Participants will take the medication in capsule form, twice a day. Throughout the study, the participants’ depressive symptoms will be monitored and assessed using various scales and questionnaires to determine any changes in their condition. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

The primary goal of this study is to see if Nelivaptan can effectively reduce depressive symptoms compared to a placebo. Participants will be regularly evaluated to track their progress and any side effects they may experience. This research could provide valuable insights into new treatment options for those suffering from Major Depressive Disorder.

]]> Study on the Safety and Effectiveness of Aticaprant with Antidepressants for Adults and Elderly with Major Depressive Disorder https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-aticaprant-with-antidepressants-for-adults-and-elderly-with-major-depressive-disorder/ Wed, 29 Apr 2026 14:58:42 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-aticaprant-with-antidepressants-for-adults-and-elderly-with-major-depressive-disorder/ This clinical trial is focused on studying the effects of a medication called aticaprant on individuals with Major Depressive Disorder (MDD). The study aims to evaluate if adding aticaprant to a current antidepressant treatment is safe and can help improve symptoms of depression. Participants in the study will continue taking their existing antidepressant, which could be a type known as an SSRI or SNRI, while also taking aticaprant.

The purpose of the study is to assess the long-term safety and tolerability of aticaprant when used alongside a current antidepressant. The study will involve taking aticaprant in the form of a tablet by mouth. Participants will be monitored over a period of up to one year to observe any changes in their condition and to ensure the treatment is safe. The study will also look at various health indicators, such as vital signs, weight, and any side effects that may occur.

Throughout the study, participants will undergo regular health checks, including physical examinations and heart tests known as ECGs, to ensure they remain in good health. The study will also assess any changes in mood or behavior, including any thoughts of self-harm, using a specific rating scale. This trial is designed to provide valuable information on whether aticaprant can be a beneficial addition to existing depression treatments.

]]> Study on the Effectiveness of Hypothalamic Phospholipids and Citalopram for Treating Major Depressive Disorder in Elderly Patients https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-hypothalamic-phospholipids-and-citalopram-for-treating-major-depressive-disorder-in-elderly-patients/ Wed, 29 Apr 2026 14:57:59 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-hypothalamic-phospholipids-and-citalopram-for-treating-major-depressive-disorder-in-elderly-patients/ This clinical trial is focused on studying the effects of a treatment for Major Depressive Disorder in elderly patients. The study involves the use of a medication called Liposom Forte, which contains hypothalamic phospholipids, and is administered as a solution for injection. The trial also includes the use of citalopram, a commonly prescribed antidepressant, in the form of film-coated tablets. Additionally, a placebo is used in the study to help assess the effectiveness of the treatment.

The purpose of the study is to determine if Liposom Forte can enhance and speed up the response to antidepressant therapy with citalopram in elderly patients suffering from Major Depressive Disorder. Participants in the study will receive either the active treatment or a placebo, and their progress will be monitored over a period of time. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the active treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will have regular visits to assess their response to the treatment. The effectiveness of the treatment will be evaluated by measuring changes in depressive symptoms using established scales. The study will also monitor the safety of the treatments by tracking any side effects or changes in health indicators. The trial aims to provide valuable information on whether Liposom Forte can improve the effectiveness of citalopram in treating depression in the elderly.

]]> Study on Aticaprant and Antidepressant for Preventing Relapse in Adults with Major Depressive Disorder and Anhedonia https://clinicaltrials.eu/trial/study-on-aticaprant-and-antidepressant-for-preventing-relapse-in-adults-with-major-depressive-disorder-and-anhedonia/ Wed, 29 Apr 2026 14:57:39 +0000 https://clinicaltrials.eu/trial/study-on-aticaprant-and-antidepressant-for-preventing-relapse-in-adults-with-major-depressive-disorder-and-anhedonia/ This clinical trial is focused on studying Major Depressive Disorder (MDD), a condition characterized by persistent feelings of sadness and loss of interest. The study specifically targets individuals with moderate-to-severe anhedonia, which is a reduced ability to feel pleasure. The treatment being tested is a medication called Aticaprant, which is taken in tablet form. It is used alongside an antidepressant, which is a type of medication that helps to relieve symptoms of depression. The purpose of the study is to evaluate how effective Aticaprant is in preventing the return of depressive symptoms in people who have already shown improvement with their current treatment.

Participants in the study will be randomly assigned to receive either Aticaprant or a placebo, which looks like the medication but does not contain the active substance. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps to ensure that the results are not influenced by expectations about the treatment. The study will take place over a period of time, during which participants will continue their usual antidepressant treatment while also taking the study medication or placebo.

The main goal is to see how long it takes for depressive symptoms to return, if they do, after starting the study treatment. This information will help researchers understand if Aticaprant can effectively delay the relapse of depression symptoms in people with MDD and anhedonia. Participants will be monitored regularly to assess their response to the treatment and to ensure their safety throughout the study.

]]> Study on Psilocybin, Ketamine, and Midazolam for Patients with Treatment-Resistant Depression https://clinicaltrials.eu/trial/study-on-psilocybin-ketamine-and-midazolam-for-patients-with-treatment-resistant-depression/ Wed, 29 Apr 2026 14:57:31 +0000 https://clinicaltrials.eu/trial/study-on-psilocybin-ketamine-and-midazolam-for-patients-with-treatment-resistant-depression/ This clinical trial is focused on studying the effects of treatments for treatment-resistant depression, a type of depression that does not improve after trying several different medications. The study will compare the effects of three different substances: psilocybin, ketamine hydrochloride, and midazolam. Psilocybin is a compound found in certain types of mushrooms, ketamine hydrochloride is a medication often used for anesthesia, and midazolam is a medication typically used for sedation. In this study, psilocybin is given in a dose of 25 mg, ketamine hydrochloride in a dose of 250 mg, and midazolam in a dose of 5 mg, all in the form of hard capsules taken orally.

The purpose of the study is to evaluate the rapid antidepressant effects of psilocybin and ketamine hydrochloride compared to midazolam, which is not expected to have antidepressant effects. Participants will receive a single dose of one of these medications, and their symptoms will be assessed 24 hours later using a scale called the MADRS scale, which measures the severity of depression. The study aims to see if psilocybin and ketamine hydrochloride have similar effects in reducing depressive symptoms and if these effects are more pronounced than those of midazolam.

Throughout the study, participants will be monitored for the duration of the antidepressant effects of each medication over a two-week period while staying in a hospital. The study will also look at how long the effects last after leaving the hospital, using the MADRS scale and another scale called the QIDS scale. Additionally, the study will track how quickly depressive symptoms return within three months after treatment and assess the safety of the medications by monitoring vital signs and other health indicators.

]]> Study on Ketamine and Midazolam for Adults with Depression and Alcohol Use Disorder https://clinicaltrials.eu/trial/study-on-ketamine-and-midazolam-for-adults-with-depression-and-alcohol-use-disorder/ Wed, 29 Apr 2026 14:56:46 +0000 https://clinicaltrials.eu/trial/study-on-ketamine-and-midazolam-for-adults-with-depression-and-alcohol-use-disorder/ This clinical trial is focused on studying the effects of ketamine on individuals who have both depression and alcohol use disorder. The trial will use a medication called Ketalar, which contains the active ingredient ketamine. Another medication involved in the study is Midazolam Accord, which contains midazolam hydrochloride. The purpose of the study is to evaluate how effective ketamine is in treating depression in adults who are also dealing with alcohol use disorder and are receiving therapy for addiction.

Participants in the study will receive treatments through intravenous infusion, which means the medication is given directly into a vein. The study will compare the effects of ketamine with those of a placebo to see if there is a significant difference in how well the depression symptoms improve. The trial will also look at changes in alcohol cravings and consumption, as well as any side effects that may occur during the treatment sessions.

The study will take place over a period of time, with participants being monitored for changes in their symptoms and overall health. The goal is to gather information on how ketamine can help people with both depression and alcohol use disorder, and to understand its impact on their mental health and alcohol consumption habits. This research aims to provide valuable insights into potential new treatment options for individuals facing these challenges.

]]> Study on Lumateperone for Patients with Major Depressive Disorder Not Responding to Antidepressants https://clinicaltrials.eu/trial/study-on-lumateperone-for-patients-with-major-depressive-disorder-not-responding-to-antidepressants/ Wed, 29 Apr 2026 14:48:00 +0000 https://clinicaltrials.eu/trial/study-on-lumateperone-for-patients-with-major-depressive-disorder-not-responding-to-antidepressants/ This clinical trial is focused on studying the effects of a medication called lumateperone in patients with Major Depressive Disorder (MDD). MDD is a mental health condition characterized by persistent feelings of sadness and loss of interest in activities. The study aims to evaluate how effective and safe lumateperone is when used alongside existing antidepressant treatments for individuals who have not responded adequately to their current medication.

Participants in the study will receive either lumateperone or a placebo, which looks like the lumateperone capsule but does not contain the active ingredient. The study will last for several weeks, during which participants will take the medication daily. The main goal is to observe changes in the severity of depression symptoms over this period. The study will also monitor any side effects or safety concerns related to the treatment.

Throughout the study, participants will have regular check-ins to assess their progress and any changes in their condition. The effectiveness of the treatment will be measured by changes in specific depression rating scales, which help to quantify the severity of symptoms. This research hopes to provide valuable insights into the potential benefits of lumateperone as an additional treatment option for those struggling with MDD.

]]> Study on Buprenorphine for Treating Severe Suicidal Thoughts in Patients with Major Depression https://clinicaltrials.eu/trial/study-on-buprenorphine-for-treating-severe-suicidal-thoughts-in-patients-with-major-depression/ Wed, 29 Apr 2026 14:29:35 +0000 https://clinicaltrials.eu/trial/study-on-buprenorphine-for-treating-severe-suicidal-thoughts-in-patients-with-major-depression/ This clinical trial is focused on studying the effects of the medication buprenorphine for individuals experiencing severe suicidal thoughts during a major depressive episode. A major depressive episode is a period characterized by a severely low mood that affects daily functioning. The study aims to determine if buprenorphine, which is typically used for pain relief, can help reduce suicidal thoughts when added to the current treatment plan. Participants in the study will receive either buprenorphine or a placebo to compare the effectiveness of the medication.

The study will explore two different doses of buprenorphine: 0.8 mg and 0.4 mg, taken as a sublingual tablet, which means it is placed under the tongue to dissolve. The goal is to find out which dose is more effective in reducing suicidal thoughts. The study will last for several weeks, during which participants will be closely monitored for any changes in their symptoms and overall well-being. Regular assessments will be conducted to track the progress of the participants, including evaluations of their mood and any side effects they may experience.

Throughout the study, participants will undergo various assessments, including psychological evaluations and possibly MRI scans, to gather comprehensive data on the effects of the treatment. The study will also collect blood and stool samples to create a biobank, which is a collection of biological samples used for research purposes. The information gathered from this trial will help researchers understand the potential benefits of using buprenorphine as an additional treatment for severe suicidal thoughts in people with major depressive episodes.

]]> Study on the Effectiveness and Safety of REL-1017 for Patients with Major Depression Who Have Not Responded to Current Treatment https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-rel-1017-for-patients-with-major-depression-who-have-not-responded-to-current-treatment/ Wed, 29 Apr 2026 14:29:33 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-rel-1017-for-patients-with-major-depression-who-have-not-responded-to-current-treatment/ This clinical trial is focused on studying the effects of a new treatment for Major Depressive Disorder (MDD), a condition characterized by persistent feelings of sadness and loss of interest. The treatment being tested is a medication called REL-1017, which contains the active ingredient dextromethadone hydrochloride. This study aims to evaluate how effective and safe REL-1017 is when used alongside existing antidepressant treatments for individuals who have not responded adequately to their current medications.

Participants in the study will be randomly assigned to receive either REL-1017 or a placebo, which looks like the real medication but does not contain the active ingredient. The study will last for 28 days, during which participants will take the medication in tablet form by mouth. Throughout the study, participants will be monitored to assess changes in their symptoms and overall well-being. The primary goal is to see if REL-1017 can help reduce symptoms of depression more effectively than the placebo.

During the trial, participants’ progress will be measured using various scales and assessments, such as the Montgomery-Åsberg Depression Rating Scale (MADRS), which helps evaluate the severity of depression. The study will also look at other factors, including any side effects experienced by participants and changes in their overall health. The results of this study could provide valuable insights into the potential benefits of REL-1017 for people with Major Depressive Disorder who have not found relief with their current treatments.

]]>